Core Viewpoint - Recently, Tianmu Technology, an AI-driven full-stack protein research and development platform, completed over 200 million RMB in A+ round financing [1][2]. Financing History - Tianmu Technology has a rapid financing history, completing four rounds of financing in just over four years, with over 100 million RMB raised in 2024 alone through Pre-A and A rounds [2]. - The financing rounds are as follows: - Seed Round: March 2022 (less than six months after establishment) - several tens of millions RMB - Pre-A Round: 2024 - undisclosed amount - A Round: November 2024 - over 100 million RMB - A+ Round: March 2026 (latest) - over 200 million RMB [3]. Company Overview - Founded in 2021 by an elite team from Shanghai Jiao Tong University, Tianmu Technology is a global leader in AI protein design, providing a comprehensive AI protein solution from design to experimental validation and commercialization across various fields such as biomedicine and synthetic biology [3]. Technological Advancements - The company has built the world's largest protein sequence dataset, containing 9 billion protein sequences and 500 million functional labels. This dataset supports the pre-training of the AI protein design model AIACCLBIO®, which features core functions of "AI-directed evolution" and "AI enzyme mining" [4]. - The new paradigm of protein design, "AIACCLBIO® automatic design + minimal experimental validation," addresses key issues in traditional protein design, such as long timeframes, high costs, low positive rates, and challenges in multi-parameter optimization, significantly enhancing product performance, shortening R&D cycles, and reducing production costs [4].